Identification of Two Novel NPM1 Mutations in Patients with Acute Myeloid Leukemia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Genetic abnormalities in adult AML are caused most frequently by somatic mutations in exon 12 of the NPM1 gene, which is observed in approximately 35% of AML patients and up to 60% of patients with cytogenetically normal AML (CN-AML). Methods: We performed mutational analysis, including fragment analysis and direct sequencing of exon 12 of the NPM1 gene, on 83 AML patients to characterize the NPM1 mutations completely. Results: In this study, NPM1 mutations were identified in 19 (22.9%) of the 83 AML patients and in 12 (42.9%) of the 28 CN-AML patients. Among the 19 patients with NPM1 mutations, type A NPM1 mutations were identified in 16 (84.2%) patients, whereas non-A type NPM1 mutations were observed in 3 (15.8%) patients. Two of the 3 non-A type NPM1 mutations were novel: c.867_868insAAAC and c.869_873indelCTTTAGCCC. These 2 novel mutant proteins display a nuclear export signal motif (L-xxx-L-xx-V-x-L) less frequently and exhibit a mutation at tryptophan 290 that disrupts the nucleolar localization signal. Conclusions: This study suggests that novel NPM1 mutations may be non-rare and that supplementary sequence analysis is needed along with conventional targeted mutational analysis to detect non-A types of NPM1 mutations.
Abstract
Background: Genetic abnormalities in adult AML are caused most frequently by somatic mutations in exon 12 of the NPM1 gene, which is observed in approximately 35% of AML patients and up to 60% of patients with cytogenetically normal AML (CN-AML). Methods: We performed mutational analysis, including fragment analysis and direct sequencing of exon 12 of the NPM1 gene, on 83 AML patients to characterize the NPM1 mutations completely. Results: In this study, NPM1 mutations were identified in 19 (22.9%) of the 83 AML patients and in 12 (42.9%) of the 28 CN-AML patients. Among the 19 patients with NPM1 mutations, type A NPM1 mutations were identified in 16 (84.2%) patients, whereas non-A type NPM1 mutations were observed in 3 (15.8%) patients. Two of the 3 non-A type NPM1 mutations were novel: c.867_868insAAAC and c.869_873indelCTTTAGCCC. These 2 novel mutant proteins display a nuclear export signal motif (L-xxx-L-xx-V-x-L) less frequently and exhibit a mutation at tryptophan 290 that disrupts the nucleolar localization signal. Conclusions: This study suggests that novel NPM1 mutations may be non-rare and that supplementary sequence analysis is needed along with conventional targeted mutational analysis to detect non-A types of NPM1 mutations.
참고문헌 (21)
- Eirín-López JM, "Long-term evolution and functional diversification in the members of the nucleophosmin", nucleoplasmin family of nuclear chaperones, 2006, pp.173, 1835~1850
- Grisendi S, "Nucleophosmin and cancer", Nat Rev Cancer, 6, pp.493~505 (2006)
- Falini B, "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype", N Engl J Med, 352, pp.254~266 (2005)
- Rau R, "Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity", Hematol Oncol, 27, pp.171~181 (2009)
- Döhner K, "Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations", Blood, 106, pp.3740~3746 (2005)
- Yu Y, "Nucleophosmin is essential for ribosomal protein L5 nuclear export", Mol Cell Biol, 26, pp.3798~3809 (2006)
- Nishimura Y, "Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization", Biosci Biotechnol Biochem, 66, pp.2239~2242 (2002)
- Falini B, "Acute myeloid leukemia carrying cytoplasmic", mutated nucleophosmin (NPMc+ AML): biologic and clinical features, 2007, pp.109, 874~885
- Falini B, "Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML", Blood, 107, pp.4514~4523 (2006)
- Mariano AR, "Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal", Oncogene, 25, pp.4376~4380 (2006)
- Koh Y, "Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype", INTERNATIONAL JOURNAL OF HEMATOLOGY, 90, pp.1~5 (2009), SPRINGER TOKYO
- Park BG, "Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia", ACTA HAEMATOLOGICA, 127(2), pp.63~71 (2012), KARGER
- Yeo-Kyeoung Kim, "Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia", Blood Research, 45(1), pp.36~45 (2010), 대한혈액학회
- Falini B, "Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?", Blood, 117, pp.1109~1120 (2011)
- Falini B, "Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications", Leukemia, 23, pp.1731~1743 (2009)
- Verhaak RG, "Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance", Blood, 106, pp.3747~3754 (2005)
- Thiede C, "Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)", Blood, 107, pp.4011~4020 (2006)
- Ahmad F, "Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population", Hematol Oncol, 27, pp.90~97 (2009)
- Yan L, "Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia", Int J Hematol, 86, pp.143~146 (2007)
- Wang W, "Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication", Nat Cell Biol, 7, pp.823~830 (2005)
- Falini B, "Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives", Curr Opin Oncol, 21, pp.573~581 (2009)